
Jonathan Gardner
Senior Reporter | @ByJonGardner801 articles by Jonathan Gardner
-
Merck suffers bad week as 3 Keytruda combination trials fail
Dec. 8, 2023 -
Biden administration goes after drug patents in bid to lower prices
Dec. 7, 2023 -
BIO names longtime Amicus head John Crowley as new CEO
Dec. 5, 2023 -
Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use
Dec. 4, 2023 -
AbbVie joins ADC dealmaking with $10B ImmunoGen buyout
Nov. 30, 2023 -
FDA names chief scientist Bumpus as Woodcock’s successor
Nov. 29, 2023 -
FDA investigating cancer risk linked to CAR-T cell therapy
Nov. 28, 2023 -
Pharma benefited from basing business overseas. An international tax effort could spur a rethink.
Nov. 28, 2023 -
GSK cancer drug Blenrep gets surprise trial win
Nov. 27, 2023 -
Bayer ends large blood thinner trial for ‘inferior efficacy’
Nov. 20, 2023 -
Lilly plans new $2.5B manufacturing plant as obesity drug demand ramps up
Nov. 17, 2023 -
Top FDA official Woodcock to retire early next year
Nov. 16, 2023 -
FDA approves new Bristol Myers drug for lung cancer
Nov. 16, 2023 -
Gilead expands Arcellx cancer cell therapy deal
Nov. 15, 2023 -
Novartis licenses Legend cell therapy for lung cancer
Nov. 13, 2023 -
Detailed trial data confirm Wegovy heart benefit
Nov. 11, 2023 -
AstraZeneca stays in GLP-1 drug race with new deal
Nov. 9, 2023 -
Lilly rival to weight loss drug Wegovy approved by FDA
Nov. 8, 2023 -
FTC challenges patents held by nine big drugmakers, citing unfair competition
Nov. 8, 2023 -
Novo, Lilly buoyed by fast-growing GLP-1 drug sales
Nov. 2, 2023 -
A play-by-play of the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy
Oct. 31, 2023 -
Sanofi to divest consumer unit, joining pharma industry shift
Oct. 27, 2023 -
Novartis delays FDA filing for in-demand radiopharma drug
Oct. 24, 2023 -
Merck cancer drug deal caps pharma investment influx into ‘ADC’ field
Oct. 20, 2023 -
Roche eye drug sales grow as Regeneron plays catch-up
Oct. 19, 2023